Although we did not directly evaluate ESR1 or PI3K/AKT gene alterations, incorporating CEACAM6 into multi-marker predictive models may enhance patient stratification and inform more personalized therapeutic approaches in HR+/HER2− breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.